Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 5 30 versus LARIN FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN FE 1 5 30 versus LARIN FE 1 20.
LARIN FE 1.5/30 vs LARIN FE 1/20
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Prevention of pregnancyTreatment of moderate acne vulgaris in females ≥15 years (if no known contraindications and have achieved menarche)Off-label: Dysmenorrhea, menstrual irregularities, endometriosis-associated pain, hirsutism
Prevention of pregnancy in women who elect to use an oral contraceptive
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
None Documented
None Documented
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Ethinyl estradiol: primarily CYP3A4 metabolism with first-pass hepatic and intestinal metabolism; undergoes conjugation (glucuronidation and sulfation). Norethindrone: extensively metabolized via reduction, glucuronidation, and sulfation; CYP3A4 also involved.
Ethinyl estradiol is metabolized primarily via CYP3A4, with sulfation and glucuronidation. Norethindrone is reduced and conjugated, primarily via CYP3A4 and other CYP450 enzymes.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Ethinyl estradiol: ~97-98% bound, primarily to albumin (70%) and sex hormone-binding globulin (SHBG). Norethindrone: ~61-63% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 97-98% (albumin, SHBG); norethindrone: 80-85% (albumin, SHBG)
Ethinyl estradiol: Vd approximately 2.5-4 L/kg; norethindrone: Vd approximately 4-5 L/kg. Distribution into breast milk and body fat is notable.
Ethinyl estradiol: 2.5-5 L/kg; norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
Ethinyl estradiol: ~40-50% due to first-pass metabolism; norethindrone: ~50-65% with first-pass metabolism. Food may increase bioavailability.
Oral: ~40% for ethinyl estradiol (first-pass metabolism); ~64% for norethindrone (range 50-75%)
Contraindicated in patients with renal impairment or renal disease.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 mL/min) may require monitoring due to potential fluid retention; use lowest effective dose.
Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). Use with caution in Child-Pugh class A, consider alternative therapy.
Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, use with caution and only if benefits outweigh risks; consider alternative methods of contraception. Child-Pugh class A: no adjustment necessary.
Not indicated for use in pediatric females before menarche. For postmenarchal pediatric patients, dosage same as adults: one tablet orally once daily for 21 days, then 7 placebo tablets.
Approved for post-menarcheal adolescents. Same dosing as adults: one active tablet daily for 21 days, then placebo for 7 days. Weight-based adjustments not required.
Not indicated for use in postmenopausal women. Safety and efficacy not established in geriatric population.
Not indicated for postmenopausal women. No specific geriatric dose adjustments, but consider increased risk of thrombotic events and manage cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events (stroke, myocardial infarction, thromboembolism) from combined oral contraceptives. Risk increases with age and number of cigarettes smoked, particularly in women >35 years. Advise not to smoke.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women >35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Increased risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, especially in smokers >35 years, hypertension, obesity, diabetes, hyperlipidemia, or migraine with aura. Monitor for undiagnosed abnormal genital bleeding, liver disease, hypertension, depression, migraine, carbohydrate/lipid effects, hereditary angioedema, chloasma, retinal thrombosis, gallbladder disease, and anaphylactic reactions. Discontinue if jaundice, vision changes, or severe headache occurs.
["Thrombotic disorders: Risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction.","Hepatic disease: Discontinue if jaundice or cholestasis develops.","Hypertension: Monitor blood pressure; may cause new-onset or worsening hypertension.","Gallbladder disease: Increased risk of gallstones.","Carbohydrate metabolism: May impair glucose tolerance.","Hypertriglyceridemia: May cause pancreatitis if elevated.","Uterine bleeding: Discontinue if unexplained amenorrhea or irregular bleeding persists.","Ocular disorders: Retinal thrombosis; discontinue if sudden partial or complete vision loss.","Depression: May recur or worsen.","Toxic shock syndrome: Associated with use of vaginal rings, but not specifically with this pill."]
Current or history of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction, or transient ischemic attack; known coagulation disorders; valvular heart disease with complications; uncontrolled hypertension; diabetes with vascular involvement; headache with focal neurological symptoms (migraine with aura) in women >35; estrogen-sensitive cancer (e.g., breast cancer); hepatic tumors or active liver disease; undiagnosed abnormal uterine bleeding; pregnancy; hypersensitivity to components; cigarette smoking in women >35 years; use with hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir).
["Thrombophlebitis or thromboembolic disorders (current or history)","Cerebrovascular or coronary artery disease (current or history)","Known or suspected breast carcinoma","Endometrial carcinoma or other estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Pregnancy (known or suspected)","Benign or malignant liver tumors (current or history)","Active liver disease (e.g., acute hepatitis, decompensated cirrhosis)","Hypersensitivity to any component of the product"]
Data Pending Review
Data Pending Review
Grapefruit or grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects; avoid concurrent consumption. No specific dietary restrictions otherwise. Iron supplement in active tablets may cause GI upset; take with food to reduce irritation.
No significant food interactions. However, grapefruit juice may slightly increase ethinyl estradiol levels; avoid large amounts. The ferrous fumarate in placebo pills may cause gastrointestinal upset; take with food if needed.
No increased risk of birth defects observed with oral contraceptives; avoid use in pregnancy due to potential for fetal harm and lack of necessity. First trimester: no consistent evidence of malformations. Second/third trimester: may cause fetal harm from estrogenic effects; discontinue if pregnancy occurs.
Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of malformations but potential for adverse effects from progestational agents and estrogen. Risk of fetal genital abnormalities with prolonged exposure.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; M/P ratio not established. May reduce milk quantity and quality. Not recommended for breastfeeding mothers until weaning complete to avoid infant exposure to sex hormones.
Contraindicated in breastfeeding. Small amounts of estrogen and progestin (norethindrone) pass into breast milk. M/P ratio: not established for this combination. May reduce milk production and quality. Use alternative contraception if breastfeeding.
Contraindicated in pregnancy; no dose adjustment applicable. Pharmacokinetic changes in pregnancy (increased clearance) may reduce efficacy if used inadvertently; use alternative contraception.
Contraindicated in pregnancy; no dose adjustments recommended as use is prohibited. No pharmacokinetic studies during pregnancy due to contraindication.
Category C
Category C
Contains norethindrone 1.5 mg and ethinyl estradiol 30 mcg; low estrogen dose, suitable for women with estrogen sensitivity; iron supplement (ferrous fumarate 75 mg) in last 7 tablets helps prevent iron deficiency; missed pill protocol: if one tablet missed, take as soon as remembered; if two missed in week 1 or 2, take two the next day and two the day after; if two missed in week 3 or three or more missed at any time, discard pack and start new pack next day, use backup contraception for 7 days.
LARIN FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg). It uses a 24/4 regimen with 24 active pills and 4 ferrous fumarate placebo pills. The iron supplements in the placebo pills help reduce the risk of iron deficiency anemia. Advise patients that spotting or breakthrough bleeding is common in the first few cycles. Monitor for hypertension, migraines, and thrombotic events. Smoking increases cardiovascular risk, especially in women over 35. LARIN FE 1/20 may decrease milk production in breastfeeding women.
Take one tablet daily at the same time, preferably after an evening meal to reduce nausea.The last 7 tablets (brown) contain iron; do not skip them even if bleeding occurs.If you miss a pill, refer to the missed pill instructions in the package insert.Use backup contraception (e.g., condoms) if pills are missed or if you start a new pack late.Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 months.Report severe abdominal pain, chest pain, shortness of breath, severe headache, or vision changes immediately.Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.This medication does not protect against sexually transmitted infections (STIs).
Take one pill daily at the same time each day. Swallow the pill whole; do not crush or chew.Start the pack on the first Sunday after your period starts (unless instructed otherwise).Use backup contraception (like condoms) for the first 7 days if you start taking the pill for the first time.If you miss a pill, refer to the package insert for instructions. Missing pills increases pregnancy risk.Common side effects include nausea, breast tenderness, and breakthrough bleeding. These often improve after a few months.Contact your healthcare provider if you experience severe abdominal pain, chest pain, sudden shortness of breath, severe headaches, vision changes, or leg pain/swelling (possible blood clots).Talk to your doctor before starting if you smoke, are over 35, have high blood pressure, migraines with aura, or a history of blood clots.The iron pills (brown tablets) are not active birth control; they are taken during the fourth week to help prevent anemia.Do not stop taking the pill without consulting your doctor.